Citi yesterday morning initiated coverage of Agios Pharmaceuticals (AGIO) with a Buy rating and $38 price target Citi also opened a “positive 30-Day catalyst watch” on Agios into the December 7 FDA action date for Pyrukynd in thalassemia. It believes the Phase 3 data support approval and thinks the recent selloff in the shares on the sickle cell disease data is overdone.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AGIO:
- Agios Pharmaceuticals initiated with a Buy at Truist
- Agios Pharmaceuticals price target lowered to $20 from $37 at JPMorgan
- Agios Pharmaceuticals price target lowered to $25 from $40 at Goldman Sachs
- Leerink upgrades Agios to Outperform after 51% pullback
- Agios Pharmaceuticals upgraded to Outperform from Market Perform at Leerink